Arca
Skip to content
Tools
Tools

CCND1, CDK4: Cyclin-dependent kinase 4/cyclin D1

Complex in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CCND1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Palbociclib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        PalbociclibApprovedPfizerSmall moleculeInhibitorCyclin-dependent kinase 4/cyclin D1 inhibitor163

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaPalbociclibPhase 1 / Phase 2Not yet recruitingSecond Affiliated Hospital of Nanchang UniversityNov 9, 2026
        A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerPalbociclibPhase 3Not yet recruitingJiangsu HengRui Medicine Co., Ltd.Oct 26, 2026
        A Phase 1/2a Study of K-1728 in Advanced Solid TumorsPalbociclibPhase 1 / Phase 2RecruitingKymaThera, Inc.Oct 6, 2026
        Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerPalbociclib—RecruitingFundación Santa Fe de BogotaOct 2, 2026
        Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerPalbociclibPhase 2Not yet recruitingFudan UniversitySep 17, 2026
        Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingPalbociclibPhase 3Not yet recruitingSWOG Cancer Research NetworkSep 3, 2026
        A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid TumorsPalbociclibPhase 1Not yet recruitingLaekna LimitedAug 26, 2026
        A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesPalbociclibPhase 2RecruitingHoffmann-La RocheAug 5, 2026

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1907601, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.